Phase III Study of KX-826 With Adult Male Patients With AGA
Status:
Active, not recruiting
Trial end date:
2024-05-31
Target enrollment:
Participant gender:
Summary
This is a phase III, multi-center, randomized, double-blind, placebo-controlled clinical
study to evaluate the efficacy and safety of KX-826 for topical use in Chinese adult male
patients with androgenetic alopecia (AGA).